Evaluation of the CD40 receptor-ligand system in the patients with atrial fibrillation of non-valvular genesis

Thromboembolic syndrome is the most dangerous complication of atrial fibrillation which develops in about 8-15% cases, thus presuming role persisting left-heart thrombosis presence anticoagulant therapy some patients. When activated, blood platelets express multiple copies CD40L on their membrane. Hence, soluble form CD40 ligand considered a marker platelet activation and pathogenic processes associated with increased activity thrombotic system. Our aim was to study content CD40, thrombomodulin patients non-valvular genesis receiving therapy, discerning those history complications, cases fibrillation, however, free complications. The group included 22 healthy volunteers 60 diagnosed who received whom 21 have developed complications course adequate therapy. Quantitative assays were performed by enzyme immunoassay using Core Facility “Medical Genomics”, Tomsk National Research Medical Center. Concentration both groups significantly exceeded appropriate values volunteers. against without Thrombomodulin serum decreased as compared thrombosis-free patients, practically CD40/CD40L system showed that exhibited higher level CD40L, simultaneous decrease thrombomodulin, physiological anticoagulant. A comparative analysis CD40/sCD40L concentrations biomarkers females, when males.